Epitalon FDA & Regulatory Status (2026)

Published reporting only; not an independently verified live regulatory determination. Sources and review dates are shown for each field.

Author: Chad E. · Last reviewed: 2026-10-17

FDA compounding category
Reported removed from Category 2 effective April 22, 2026. This report does not establish a later Category 1 placement. Source post
Reviewed: 2026-10-17
PCAC review and vote
July 24, 2026: recommended for inclusion, 7–5 with one abstention. The vote is advisory. Source post
Reviewed: 2026-10-17
503A bulks list status
The cited coverage describes an advisory recommendation, not completed FDA rulemaking or a final bulks-list addition. Source post
Reviewed: 2026-10-17
FDA-approved drug
Not yet reviewed
WADA status
Listed in our 2026 WADA coverage as prohibited under S0. Source post
Reviewed: 2026-10-17

Recent developments

Sourced questions

What FDA category is Epitalon in?

Reported removed from Category 2 effective April 22, 2026. This report does not establish a later Category 1 placement.

What did the PCAC vote on Epitalon?

July 24, 2026: recommended for inclusion, 7–5 with one abstention. The vote is advisory.

Is Epitalon on the 503A bulks list?

The cited coverage describes an advisory recommendation, not completed FDA rulemaking or a final bulks-list addition.

Is Epitalon banned by WADA?

Listed in our 2026 WADA coverage as prohibited under S0.

Encyclopedia entry · State-law reference

Research use only. Not for human consumption. This page summarizes public regulatory information and is not legal advice.